Background Immunotherapies targeting immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, the majority of patients do not benefit from current treatments. Another barrier to success of ICI therapies which is often overlooked is the development of immune-related adverse events (irAEs) in immunotherapy responders. Failure of treatment strategies to mitigate serious irAE symptoms while maintaining immunotherapy efficacy results in abrupt termination of immunotherapy and toxic fatalities. One major obstacle for clinicians has been the poor understanding of immunopathology of irAEs due to lack of a preclinical disease model. Methods We have developed an irAE mouse model, termed the Lifestyle Induced Susceptibility to irAEs (LISA). This model combines dietary and microbiome changes using a Western Diet (WD) that is composed of higher fat and simple carbohydrates. LISA mice were then subjected to 3 weeks of ICI therapies (anti-PD1, anti-CTLA4, anti-LAG3, or a combination). Disease severity and immune function were assessed through histopathology, flow cytometry, multispectral imaging, and single cell RNAseq. Results The LISA model showed systemic onset of irAEs across different mouse strains, including overt inflammation within the skin, gastrointestinal tract, and liver. Similar to patients, we found an association between irAE severity and host factors, including sex, age, and treatment modality (anti-PD1 vs. combination), and duration of diet exposure. Single cell RNAseq analysis revealed an upregulation of cycling CD8 + T cells and inflammatory CD4+ Tregs. Further analysis suggested that Tregs isolated from the LISA model were unstable and expressed inflammatory markers including T-bet and IFNγ. Analysis of specific roles of diet and microbiome in generation of irAEs showed that while exposure to WD itself could promote Treg dysfunction, the microbiome was necessary and sufficient to drive systemic irAE symptoms. Conclusions We have generated the first of its kind mouse model of irAEs which is simple yet effective in replicating the clinical phenotypes of irAEs in cancer patients. Through this model, we have identified potential mediators and immune drivers of irAE severity, including Treg instability. Overall, the LISA model has significant potential to not only develop a deeper understanding of irAEs, but to also uncover new treatment modalities for patients experiencing toxicity after immunotherapy. Ethics Approval The study obtained ethics approval from the Institutional Animal care and use comittee (IACUC) and the Institutional review board (approval number 22071386).